Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chih-Lin Lin

Showing results (111-120 of 132) with videos related to

Pageof 14
Sort By:
Open Forum Infectious Diseases|August 5, 2022
Hepatitis C Virus Reinfection in People With HIV in Taiwan After Achieving Sustained Virologic Response With Antiviral Treatment: The RECUR StudyChen-Hua Liu, Hsin-Yun Sun, Cheng-Yuan Peng, et al.
Hepatology (Baltimore, Md.)|January 17, 2013
Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-upMing-Lung Yu, Chuan-Mo Lee, Chi-Ling Chen, et al.
Gut|January 20, 2026
Steatosis grade and cardiometabolic burden as determinants of hepatocellular carcinoma risk after hepatitis C cure in patients with metabolic dysfunction-associated steatotic liver diseaseYu-Ping Chang, Yun-Chu Chen, Pin-Nan Cheng, et al.
Gastroenterology|December 17, 2008
Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C virusesChun-Jen Liu, Wan-Long Chuang, Chuan-Mo Lee, et al.
Clinical and Molecular Hepatology|October 4, 2023
Taiwan Association for the Study of the Liver-Taiwan Society of Cardiology Taiwan position statement for the management of metabolic dysfunction- associated fatty liver disease and cardiovascular diseasesPin-Nan Cheng, Wen-Jone Chen, Charles Jia-Yin Hou, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|November 2, 2024
Addition of neutrophil-to-lymphocyte ratio to Pre-DAA FIB-4 does not increase prediction value for de novo liver complications in hepatitis CChun-Ming Hong, Tung-Hung Su, Shih-Jer Hsu, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|September 17, 2016
Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patientsTung-Hung Su, Tsung-Hui Hu, Chi-Yi Chen, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|March 1, 2025
Posttreatment FIB-4 score change predicts hepatocellular carcinoma in chronic hepatitis C patients: Findings from the Taiwan hepatitis C registry programHung-Wei Wang, Yu-Syuan Zeng, Chung-Feng Huang, et al.
Scientific Reports|December 7, 2021
Nationwide registry of glecaprevir plus pibrentasvir in the treatment of HCV in TaiwanChung-Feng Huang, Hsing-Tao Kuo, Te-Sheng Chang, et al.
The Kaohsiung Journal of Medical Sciences|June 20, 2025
Effects of Sofosbuvir/Velpatasvir Therapy on Extrahepatic Manifestations in Patients With Type 2 Diabetes and Chronic Hepatitis C: Insights From a Nationwide Hepatitis C Virus Registry in TaiwanSzu-Jen Wang, Te-Sheng Chang, Ching-Chu Lo, et al.
Pageof 14

Showing results (111-120 of 132) with videos related to

Sort By:
Pageof 14
Open Forum Infectious Diseases|August 5, 2022
Hepatitis C Virus Reinfection in People With HIV in Taiwan After Achieving Sustained Virologic Response With Antiviral Treatment: The RECUR StudyChen-Hua Liu, Hsin-Yun Sun, Cheng-Yuan Peng, et al.
Hepatology (Baltimore, Md.)|January 17, 2013
Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-upMing-Lung Yu, Chuan-Mo Lee, Chi-Ling Chen, et al.
Gut|January 20, 2026
Steatosis grade and cardiometabolic burden as determinants of hepatocellular carcinoma risk after hepatitis C cure in patients with metabolic dysfunction-associated steatotic liver diseaseYu-Ping Chang, Yun-Chu Chen, Pin-Nan Cheng, et al.
Gastroenterology|December 17, 2008
Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C virusesChun-Jen Liu, Wan-Long Chuang, Chuan-Mo Lee, et al.
Clinical and Molecular Hepatology|October 4, 2023
Taiwan Association for the Study of the Liver-Taiwan Society of Cardiology Taiwan position statement for the management of metabolic dysfunction- associated fatty liver disease and cardiovascular diseasesPin-Nan Cheng, Wen-Jone Chen, Charles Jia-Yin Hou, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|November 2, 2024
Addition of neutrophil-to-lymphocyte ratio to Pre-DAA FIB-4 does not increase prediction value for de novo liver complications in hepatitis CChun-Ming Hong, Tung-Hung Su, Shih-Jer Hsu, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|September 17, 2016
Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patientsTung-Hung Su, Tsung-Hui Hu, Chi-Yi Chen, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|March 1, 2025
Posttreatment FIB-4 score change predicts hepatocellular carcinoma in chronic hepatitis C patients: Findings from the Taiwan hepatitis C registry programHung-Wei Wang, Yu-Syuan Zeng, Chung-Feng Huang, et al.
Scientific Reports|December 7, 2021
Nationwide registry of glecaprevir plus pibrentasvir in the treatment of HCV in TaiwanChung-Feng Huang, Hsing-Tao Kuo, Te-Sheng Chang, et al.
The Kaohsiung Journal of Medical Sciences|June 20, 2025
Effects of Sofosbuvir/Velpatasvir Therapy on Extrahepatic Manifestations in Patients With Type 2 Diabetes and Chronic Hepatitis C: Insights From a Nationwide Hepatitis C Virus Registry in TaiwanSzu-Jen Wang, Te-Sheng Chang, Ching-Chu Lo, et al.
Pageof 14